Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 15/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4877133 | 0.90 | P2RY12 (0.56) | P2RY12ALDH1A1KDM4EL3MBTL1LMNA | |
| SCHEMBL3221673 | 0.87 | P2RY12 (0.69) | P2RY12KDM4ECYP3A4CYP2C9 | |
| SCHEMBL4740960 | 0.85 | P2RY12 (0.57) | P2RY12ALDH1A1KDM4EL3MBTL1LMNA | |
| SCHEMBL5064038 | 0.85 | ALDH1A1 (0.63) | P2RY12ALDH1A1KDM4EL3MBTL1LMNA | |
| SCHEMBL3328558 | 0.84 | P2RY12 (0.56) | P2RY12ALDH1A1KDM4EL3MBTL1LMNA | |
| SCHEMBL3327054 | 0.84 | P2RY12 (0.56) | P2RY12ALDH1A1KDM4EL3MBTL1LMNA | |
| SCHEMBL5053551 | 0.84 | ALDH1A1 (0.65) | P2RY12ALDH1A1KDM4EL3MBTL1LMNA | |
| SCHEMBL3328347 | 0.84 | L3MBTL1 (0.56) | P2RY12ALDH1A1KDM4EL3MBTL1LMNA | |
| SCHEMBL3585012 | 0.84 | P2RY12 (0.55) | P2RY12ALDH1A1KDM4EL3MBTL1LMNA | |
| SCHEMBL4871507 | 0.84 | P2RY12 (0.55) | P2RY12ALDH1A1KDM4EL3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312208-A1 | Pyridine Analogues | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| EP-1904474-A1 | NEW PYRIDINE ANALOGUES | AstraZeneca AB (SE) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007008140-A1 | NEW PYRIDINE ANALOGUES | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312208-A1 | Pyridine Analogues | P2RY12, P2RY11, P2RY1 | P2RY12 1/4885ALDH1A1 1274/4885KDM4E 1759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.